Onco Actu du 21 avril 2017

	2.4 Etiologie - Portables, ondes e-m
Italian court rules mobile phone use caused brain tumour [The Guardian] In what could become a landmark ruling, the court in the northern town of Ivrea awarded the plaintiff a state-funded pension.
	2.5 Etiologie - Gènes
Some genetic nonsense about non-sense genes [The Mermaid's Tale] We have no reason to question the technical accuracy of the papers, nor their relevance to biomedical and other genetics, but there are reasons to assert that this is nothing newly discovered, and that the story misses the really central point that should, I think, be undermining the expensive Big Data/GWAS approach to biological causation.
	4.2 Dép., diag. & prono. - Génome
The Go-To Gene Sequencing Machine With Very Strange Results [Wired] Sinha wasn’t the first person to notice something funny in the HiSeq 4000’s results. Rumors have been swirling in corners of the internet ever since Illumina introduced the ExAmp technology.
When Even Genome Sequencing Doesn’t Give a Diagnosis [MIT Technology Review] Isaac Kohane, of Harvard Medical School’s Department of Biomedical Informatics, says people analyzing a genome might simply miss a cause lying in plain sight—a so-called false negative. “Our ability to distinguish what actually might cause disease is still quite crude,” Kohane says. “So we have an unknown false-negative rate.”
	4.9 Dép., diag. & prono. - Sein
When to Tell Daughters About a Genetic Breast Cancer Risk [NY Times] Dr. Ruth Oratz, a medical oncologist and breast cancer specialist at NYU Langone’s Perlmutter Cancer Center, worries that parents who inform their children about a potential genetic risk do not alleviate anxiety but instead hamper their teenager’s ability to live freely.
	5. Traitements
Experimental drug could lead to potent combination in breast and other cancers [Institute for Cancer Research] In the study, the scientists treated 91 cancer cell lines with the compound, called CCT271850. They found that more than half the cell lines were sensitive to MPS1 inhibition, with colon cancer, head and neck cancer and breast cancer cells particularly so.
	5.12.2 Immunothérapies - CAR-T
Novartis drug development chief outlines CAR-T research commitment [FierceBiotech] “We have the scale to work on these sorts of things quickly. So, the integration has allowed us to work on multiple programs in parallel, where I think the unit was focusing on just one or two programs at a time.”
	5.2.1 Pharma - Partenariats
H3 Biomedicine boosts its cancer collab with Foundation Medicine [FierceBiotech] “The genomics data in FoundationCORE is a better reflection of patients seeking treatment in current clinical practice compared with publicly available data sets, and it will continue to evolve as new therapies are adopted.”
	5.4 Traitements - Economie
Ipsen in talks with NICE over Cabometyx rejection [PharmaTimes] Ipsen says discussions with the National Institute for Health and Care Excellence are ongoing following a second rejection of Cabometyx for advanced renal cell carcinoma (RCC).
	5.5 ASCO
World’s Largest Clinical Cancer Research Meeting to Highlight Latest Advances in Patient and Survivor Care [ASCO] The theme of the 2017 ASCO Annual Meeting is Making a Difference in Cancer Care With You. The conference attracts more than 30,000 oncology professionals from around the world.
	5.5.1.1 ASCO (général) - Industriels
AVEO Announces Presentations at the 2017 ASCO Annual Meeting [Aveo] Among these is a Trials in Progress presentation highlighting the ongoing Phase 3, randomized, controlled, multi-center, open-label TIVO-3 study comparing tivozanib, the Company’s potent, selective, long half-life inhibitor of all three vascular endothelial growth factor (VEGF) receptors, to sorafenib in subjects with refractory advanced renal cell carcinoma.
Genmab Announces Data to be Presented at 2017 ASCO Annual Meeting [Genmab] Two daratumumab oral presentations and five daratumumab poster presentations.
	6.10.1 Politiques (USA)
Pharma, Big Tobacco Opened Up Wallets For Trump’s Inauguration [KHN] The industries, which are often the focus of federal scrutiny, ponied up millions for the new president's inauguration festivities.
	6.6 Publications
A new record: Major publisher retracting more than 100 studies from cancer journal over fake peer reviews [Retraction Watch] Springer, the publisher of Tumor Biology through 2016, told us that an investigation produced “clear evidence” the reviews were submitted under the names of real researchers with faked emails.
It Takes a Village: One Year of Journals Requiring ORCID iDs [The Scholarly Kitchen] The ORCID experience demonstrates that a scholarly research community “village” approach really can work. Today, well over 1,500 journals published by 16 publishers and societies, require iDs for at least their corresponding authors and, from our conversations with leaders of organizations across all sectors, we know that similar approaches are actively being considered by organizations in other sectors.
	6.7 DMP, Big Data & applis
Google’s Scary, Important, Invasive, Deep New Health Study [Wired] When it comes to big, ambitious science conducted on human beings, you have to ask: Who benefits? Is it you? Other people? Or the people collecting the data?
	6.9 Controverses
Rift widens over Huntsman Cancer Institute CEO’s firing [Salt Lake Tribune] Several Huntsman family members, whose charitable largess helped found the institute, said they were not informed in advance of CEO and Director Mary Beckerle's termination.
University of Utah Health Statement on Huntsman Cancer Institute Leadership Change [University of Utah] The difficult decision to make a change in leadership of the University of Utah’s Huntsman Cancer Institute came only after thoughtful consideration and careful deliberation, and with the full support of the University’s President and senior leaders of the Board of Trustees.